EPH112 Economic Impact of Rapid Treatment Initiation of HIV with Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) from a Canadian Healthcare Perspective

Abstract

Authors

K. Guinan K. Mathurin J. Lachaine

Full Text Cite This Article
Back to Volume 26, Supplemental Issue 6S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×